

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2913281

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ROCHE DIAGNOSTICS INTERNATIONAL AG	06/11/2014
RECEIVING PARTY DATA	
Name:	Roche Diagnostics Operations, Inc.
Street Address:	9115 Hague Road
City:	Indianapolis
State/Country:	INDIANA
Postal Code:	46250
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14264377
CORRESPONDENCE DATA	
Fax Number:	(317)521-2883
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	317-521-3104
Email:	jackie.pike@roche.com
Correspondent Name:	KENNETH J. WAITE
Address Line 1:	9115 HAGUE ROAD
Address Line 4:	INDIANAPOLIS, INDIANA 46250
ATTORNEY DOCKET NUMBER:	30662 US-PD
NAME OF SUBMITTER:	KENNETH J. WAITE
SIGNATURE:	/Kenneth J. Waite/
DATE SIGNED:	06/25/2014
Total Attachments: 1	
source=Assignment_RDI_AG-RDOI#page1.tif	

PATENT APPLICATION ASSIGNMENT

WHEREAS, Roche Diagnostics International AG ("ASSIGNOR"), a corporation of Switzerland, having its principal office at Forrenstrasse 2, CH-6343 Rotkreuz, Switzerland, owns U.S. Patent Application Serial No. 14/264,377 filed April 29, 2014, entitled, **DYNAMIC OF SFLT-1 OR ENDOGLIN/PLGF RATIO AS AN INDICATOR FOR IMMINENT PREECLAMPSIA AND/OR HELLP SYNDROME**; and

WHEREAS, Roche Diagnostics Operations, Inc. ("ASSIGNEE"), a Delaware corporation, having its principal office at 9115 Hague Road, Indianapolis, Indiana 46250, United States of America, desires to acquire the entire right, title and interest in the Application;


NOW, THEREFORE, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers all rights, title and interest in the Application, including any divisions, continuations, continuations-in-part, reexaminations, reissues, extensions, or other U.S. patent applications claiming the benefit of the filing date of the Application, to ASSIGNEE, its successors and assigns.

ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue any United States Letters Patent which may issue for the Application, including any divisions, continuations, continuations-in-part, reexaminations, reissues or extensions thereof, to ASSIGNEE, its successors and assigns.


ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and that ASSIGNOR will execute such additional writings and do such additional acts as ASSIGNEE, its successors and assigns, may deem necessary or desirable to perfect its enjoyment of this assignment, and render all necessary assistance in making application for and obtaining original, divisional, continuation, continuation-in-part, reissued, reexamined or extended Letters Patent of the United States of America that may issue from the Application.

Roche Diagnostics International AG

Date: June 11, 2014

Signature: 
Printed Name: Dr. Aden Behms
Title: Vice President, Patents

Date: June 11, 2014

Signature: 
Printed Name: Dr. Barbara Herren
Title: Holder of procurement, Patents